Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXTRIPHYLLINE PEDIATRIC vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Symptomatic relief and prevention of bronchial asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Hepatic via CYP1A2, CYP2E1, and CYP3A4; major metabolite is 1-methyl-3-propylxanthine; exhibits non-linear kinetics at high doses.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
55-65% (primarily albumin).
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.4-0.6 L/kg (increased in premature neonates and hepatic disease).
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral immediate-release: 90-100%; Sustained-release: 80-95% (relative to immediate-release).
Oral: 40-50%; Inhalation: 20-30%
No specific guidelines; consider dose reduction in severe renal impairment (GFR <30 m L/min) to avoid accumulation.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: reduce dose by 75% or avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
1-9 years: 4 mg/kg/dose orally every 6 hours; 9-16 years: 3 mg/kg/dose orally every 6 hours; adjust based on serum theophylline levels (target 5-15 mcg/m L).
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at 200 mg orally every 12 hours (extended-release) and titrate slowly; monitor serum theophylline levels closely due to reduced clearance.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA boxed warning.
No FDA black box warning.
Risk of toxicity (seizures, cardiac arrhythmias) at serum levels >20 mcg/m L,Reduce dose in hepatic impairment, heart failure, and with drugs that inhibit metabolism (e.g., cimetidine, ciprofloxacin),Monitor serum theophylline concentrations
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to oxitriphylline or any xanthine,Active peptic ulcer disease,Seizure disorder (unless adequately controlled)
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate). High-fat meals may delay absorption; consistency in timing relative to meals is recommended. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance, reducing efficacy.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Oxtriphylline, a theophylline derivative, is classified as pregnancy category C. First trimester: Limited data, no known major malformations in humans; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: No specific risks, but maternal respiratory depression and fetal tachycardia may occur with high doses. Perinatal: Apnea, irritability, and jitteriness reported in neonates due to transplacental passage.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline (active metabolite) is excreted into breast milk; M/P ratio approximately 0.6-0.8. Peak milk concentration occurs 2-3 hours after dose. Recommendations: Caution in preterm infants due to immature clearance; observe for irritability, insomnia, or feeding intolerance. Avoid if maternal dose exceeds moderate levels.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy may reduce clearance and increase half-life of theophylline; volume of distribution increases slightly. Consider 20-30% dose reduction and monitor levels to avoid toxicity (target trough 8-12 mcg/m L). Third trimester: Dose may need further adjustment; postpartum levels may decrease (clearance returns to prepregnancy levels).
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Oxtriphylline is the choline salt of theophylline, providing 64% anhydrous theophylline by weight. Monitor serum theophylline levels, maintaining therapeutic range 5-15 mcg/m L. Avoid in patients with active peptic ulcer disease or seizure disorders unless on anticonvulsants. Taper dose to avoid rebound bronchospasm. Use with caution in hepatic impairment, COPD, and elderly, as clearance is reduced.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid taking with large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report symptoms of toxicity: persistent nausea, vomiting, severe headache, rapid or irregular heartbeat, or seizures.,Do not change brands or formulations without consulting your healthcare provider.,Inform all healthcare providers that you are taking this medication.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
"Oxtriphylline, a xanthine derivative, is a prodrug of theophylline and is primarily metabolized by hepatic cytochrome P450 enzymes, notably CYP1A2 and CYP3A4. Nevirapine, a non-nucleoside reverse transcriptase inhibitor, induces CYP3A4 and other metabolic enzymes, potentially increasing the clearance of oxtriphylline's active metabolite theophylline. This reduction in theophylline exposure may decrease its bronchodilator efficacy, leading to worsening of respiratory symptoms in patients with asthma or COPD."
"Oxtriphylline, a xanthine bronchodilator, is metabolized primarily by CYP1A2 and CYP3A4. Azithromycin, a macrolide antibiotic, can inhibit CYP3A4, leading to decreased clearance of oxtriphylline and increased plasma concentrations. This may result in dose-related toxicity, including nausea, vomiting, tachycardia, and seizures."
"Oxtriphylline, a xanthine derivative used as a bronchodilator, may inhibit the metabolism of abiraterone, a CYP3A4 substrate, leading to increased serum concentrations of abiraterone. This elevation can potentiate the risk of abiraterone-related adverse effects such as hepatotoxicity, hypertension, hypokalemia, and fluid retention. Additionally, Oxtriphylline's own clearance may be affected, increasing the likelihood of xanthine toxicity manifesting as nausea, vomiting, or cardiac arrhythmias."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXTRIPHYLLINE PEDIATRIC vs AEROLATE III, answered by our medical review team.
OXTRIPHYLLINE PEDIATRIC is a Bronchodilator that works by Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXTRIPHYLLINE PEDIATRIC and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXTRIPHYLLINE PEDIATRIC is: 200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXTRIPHYLLINE PEDIATRIC and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXTRIPHYLLINE PEDIATRIC is classified as Category C. Oxtriphylline, a theophylline derivative, is classified as pregnancy category C. First trimester: Limited data, no known major malformations in humans; animal studies show no terat. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.